TP53 and neoplasm: Follow-up studies of archived tumor samples in a long-term survivor (>12 years) of metastatic pancreatic cancer following repeated infusions of DeltaRex-G, revealed a p53 (TP53) mutation (G199V) associated with an increased anti-apoptotic survival function, affirming the therapeutic efficacy of DeltaRex-G in the background of p53 suppressor mutations (Morse et al., 2021).